[Treatment of interstitial pulmonary fibrosis with D-penicillamine in progressive scleroderma: a long-term study (author's transl)].
5 patients suffering from progressive scleroderma with interstitial pulmonary fibrosis have been treated since 1971 with D-penicillamine (Artamin) as basic therapeutic agent. All patients showed a significant tendency towards normalization of the pathological findings in regard to functional capacity of the lungs and scintigraphic and radiological assessment. These results, in our opinion, justify the recommendation of a new indication for D-penicillamine therapy, namely in cases of progressive scleroderma with interstitial pulmonary fibrosis.
D000368:Aged; D004341:Drug Evaluation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010396:Penicillamine / Q000627:therapeutic use*; D011658:Pulmonary Fibrosis / Q000175:diagnosis / Q000188:drug therapy*; D012595:Scleroderma, Systemic / Q000150:complications* / Q000188:drug therapy
D007166:Immunosuppressive Agents; D010396:Penicillamine
Zur Behandlung der interstitiellen Lungenfibrose mit D-Penicillamin bei progressiver Sklerodermie (Langzeitstudie)